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cascade. Using factor IX (FIX)-deficient plasma, the assay can be used to measure FIX activity level or to monitor FIX replacement therapy in Haemophilia B patients. In Europe, in accordance with the European rFIX products compared to the OSC method. 2, 3 There are also assay discrepancies within the OSC method depending upon the choice of APTT reagent and this is especially marked for the EHL products. [4] [5] [6] In some instances, this has led to particular types of APTT reagents being recommended or avoided. [7] [8] [9] During the collaborative study performed in order to replace the 4th International Standard for FIX Concentrate (07/182), 10 a discrepancy in potency estimates was observed between some laboratories. The study included 2 rFIX candidates and 2 pdFIX candidates and it was noted that 2 laboratories using the same APTT reagent (DAPTTIN) reported potencies for the rFIX candidates that were approximately 20% lower compared to the rest of the participating laboratories, including a third laboratory that used DAPTTIN. The potency estimates for the 2 pdFIX candidates were in good agreement between the 2 laboratories and with the other laboratories. One of the major differences between these two laboratories was the activation time used for the DAPTTIN reagent.
The present study was designed to investigate the discrepancies observed for rFIX with the APTT reagent DAPTTIN. To determine if other APTT reagents produced similar issues, 2 other APTT reagents were included: SynthASil and SynthAFax. Activation times can vary across APTT reagents used for the one-stage clotting assay, so activation times of 120, 180, 240 and 300 seconds were used. In addition, 3 different FIX-deficient plasma sources were used. pdFIX1 (14/148) 10.5 IU/mL, pdFIX2 (07/224) 12.6 IU/mL; rFIX1 (07/142) 9.5 IU/mL; rFIX2 (14/180) 9.4 IU/mL. 
| MATERIAL S AND ME THODS

| Samples
| One-stage clotting assays
| Clotting factor screening assays on FIXdeficient plasmas
The 3 different FIX-deficient plasmas were assayed for their con- 
| RE SULTS
The geometric mean potencies for each activation time for each APTT reagent are shown in Table 1 . For SynthAFax, the potencies of 10.3 IU/mL and 12.8 IU/mL for pdFIX1 and pdFIX2 agreed well with the assigned potencies of 10.5 IU/mL and 12.6 IU/mL, respectively.
Neither activation time nor deficient plasma source had an effect on potency (Table 1 and Figure 1A ). Samples rFIX1 and 2 have assigned potencies of 9.5 and 9.4 IU/mL, respectively, by collaborative study and the estimated geometric mean potencies of 7.3 IU/mL and 6.8 IU/mL for rFIX1 and rFIX2 by SynthAFax were over 20% lower than expected. For SynthAFax, recombinant FIX potency estimates were not affected by activation time or by the source of deficient plasma (Table 1 and Figure 1B ).
When SynthASil was used as the APTT reagent, the pdFIX samples had observed geometric mean potencies of 10.5 IU/mL and 13.1 IU/mL for pdFIX1 and pdFIX2, respectively (Table 1 ). These were in close agreement with the assigned values and were not affected by activation time or plasma source ( Figure 2A ). For the rFIX samples, the overall geometric mean potencies of 10.7 and 10.0 IU/ mL for rFIX1 and 2 (Table 1) , respectively, were slightly higher than the assigned potencies, and remained constant across activation times. When using plasma P2, the observed potencies (10.1 and 9.4 for rFIX1 and 2, respectively) were approximately 10% lower than for P1 (11.1 and 10.5) or P3 (10.9 and 10.3; Figure 2B ). This trend was present across all activation times but was not always statistically significant.
The results obtained using DAPTTIN (Figure 3) show that the variability was greater in general than for SynthAFax or SynthASil, for both pdFIX and rFIX samples. Potencies for pdFIX1 and pdFIX2
were consistent across activation time and source of plasma ( Figure 3A ) and the estimated geometric mean potencies of 10.4 and 12.8 IU/mL for pdFIX1 and 2 (Table 1) , respectively, were close to their assigned potencies. For the rFIX samples, the observed potencies were affected by activation time, with the potencies decreasing as activation time increased (Table 1 and Figure 3B ). Depending on the plasma used, the potencies decreased by between 8 and 29% at 300 seconds, compared to 120 seconds. The differences in potencies at 300 seconds were statistically significant to those at 120 seconds. In addition, for DAPTTIN, lower potencies were observed for rFIX1 and 2 with plasma P2 than for P1 or P3 ( Figure 3B ), but these were not always significant.
To investigate whether the trend for lower potencies observed when using plasma P2 was caused by a shortage of another intrinsic clotting factor additional to FIX, clotting factor assays were carried out. Each plasma sample P1, P2 and P3 was assayed for factors II, V, VIII, X, XI and XII. The results (Table 2) show that P2 had levels of clotting factors that were similar to either P1 or P3 for factors II, VIII, XI and XII. For factors V and X, although the content in P2 would not be considered to be deficient, 13 the levels were statistically different to both P1 and P3, as shown by non-overlapping 95% confidence limits.
It is interesting to note that the levels of some clotting factors were different between the different plasma sources, though it is unlikely that the levels were low enough to have had a major impact on the potencies observed. Similarly, although fibrinogen levels were not measured, all plasmas were able to form visible clots and at similar times in the OSC assays, therefore any differences in fibrinogen content would be unlikely to explain the observed differences between the plasmas. The overall GM for each sample for each activated partial thromboplastin time (APTT) reagent is also shown. The data include the overall results from the 3 different FIX-deficient plasmas used. Potencies are shown in IU/mL.
TA B L E 1 Geometric mean (GM) of potencies of pdFIX1 and 2 and rFIX1 and 2 measured by one-stage clotting assay across activation time, for each APTT reagent
| D ISCUSS I ON
The one-stage clotting assay for FIX is an important assay used to potency label FIX therapeutics and to monitor patients undergoing therapy. There are many different APTT reagents available commercially, and each one will be different in terms of phospholipid composition and activator. In this study, we found that the potencies of rFIX preparations can be influenced by the choice of APTT reagent and activation time, when assayed relative to the International Standard for FIX (a pdFIX). Using SynthAFax, the potencies of rFIX were lower than expected, by around 20%. This difference was consistent across the activation times studied. DAPTTIN generated lower rFIX potencies; however, this was activation time-dependent, with longer activation times resulting in lower potencies. Observed potencies of pdFIX samples were as expected with either APTT reagent and neither pdFIX nor rFIX potencies were adversely affected when SynthASil was used as the APTT reagent. One possible explanation for the differences could be the composition of the APTT reagents.
Both DAPTTIN and SythASil have silica activators, with DAPTTIN containing sulfatides and silica, and SynthASil containing colloidal silica. In contrast, SynthAFax uses ellagic acid. SynthAFax has previously been shown to underestimate rFIX potency 2, 6 and APTT reagents using silica as an activator may over-estimate rFIX potency. 6 Discrepancies between ellagic acid and silica activators in APTT reagents have been well documented for extended half-life products. [4] [5] [6] The product inserts for some rFIX and extended half-life products make reference to the fact that different APTT reagents can produce different results [7] [8] [9] and as such state that APTT reagents for patient monitoring should be chosen carefully.
In this study, we used different activation times in the one-stage clotting assays. Activation times of 120, 180, 240 and 300 seconds were were used on a different machine, a different activation time could be selected by the user in the absence of any guidance. For DAPTTIN, the product insert states that 120 seconds should be used for manual tests, but that the time should be optimized between 120 and 300 seconds for automated coagulometers. Again, this could lead to different activation times being chosen in different laboratories. The influence of activation time on one-stage clotting assay potency estimates has not been extensively studied, though a decrease in rFIX potency has been noted as activation time increased. 2, 3 This was attributed to a reduction in the FIXa generated by rFIX, compared to pdFIX. 3 This could account for the difference in potencies for the rFIX samples in this study since potency is assessed relative to a pdFIX international standard. It could also be that FIXa produced from rFIX is less stable or more easily inhibited than FIXa from pdFIX, and therefore leads to a reduction in the measured potency over time. In this study, the decrease in rFIX potency over time was only observed with the APTT reagent DAPTTIN, therefore it is likely that there are other contributing factors.
Recombinant FIX is expressed in Chinese Hamster Ovary cells, so whilst the amino acid sequence is the same as pdFIX, the amino terminal glutamic acid (Gla) residues are γ-carboxylated differently.
14 Gla residues have been reported to be involved in phospholipid and calcium binding 15 and also recognition of FIX by factor XIa. 16 Subtle differences in the γ-carboxylation could explain the different behaviours of rFIX because both the formation of the tenase complex (phospholipid, factor VIIIa, factor X, FIXa and calcium) and binding to factor XIa could be altered. It has previously been noted that phospholipid concentration and composition affect potency estimates of the recombinant factor VIII, [17] [18] [19] so the effect could be similar for recombinant FIX and more evident when using DAPTTIN. Differences between rFIX potencies measured by chromogenic assays compared to one-stage clotting assays have been observed 2 and are probably due to small differences in the activation of rFIX compared to pdFIX.
One study using plasma samples from patients treated with pdFIX or rFIX showed that the peak thrombin generated by rFIX was less than that of pdFIX, 20 indicating that rFIX responds differently to activation. There has also been a report that activated factor XI can directly activate factor X, 21 thereby bypassing factors VIII and IX, so it is possible that this could be a contributing factor if the phospholipid in DAPTTIN provides a more favourable environment for this to occur. Finally, DAPTTIN is supplied as a freeze-dried reagent TA B L E 2 Measured levels of factors II, V, VIII, X, XI and XII in FIX-deficient plasmas P1 (Technoclone immunodepleted), P2 (Hyphen-Biomed immunodepleted) and P3 (Technoclone native) using one-stage clotting assays which must be reconstituted before use. In this study, a higher variability was observed generally with DAPTTIN, despite the use of a stir bar on the ACL TOP automated coagulometer. It could be that some settling of the components occurs during the activation phase, preventing optimum formation of the phospholipid/factor X/factor V complex and an apparent reduction in potency. The formation of this complex could also explain why, in some instances, plasmas P1
and P3 produced higher potencies than P2 because plasma P2 has lower levels of factors V and X and therefore the complex may be less easily formed due to the lower abundance of the constituents.
In summary, this study has shown that there can be wide 
